Spark Therapeutics Enters into Definitive Merger Agreement with Roche
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Mizuho Securities Downgrades Spark Therapeutics (ONCE) to Neutral Following Acquisition
February 25, 2019 8:55 AM ESTMizuho Securities analyst Difei Yang downgraded Spark Therapeutics (NASDAQ: ONCE) from Buy to Neutral with a price target of $114.50.
For an analyst ratings summary and ratings history on Spark Therapeutics click here. For more ratings news on Spark Therapeutics click here.
Shares of Spark Therapeutics closed at $113.85 yesterday.
... More